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DNAmethylation at promoters is an important determinant of gene
expression. Earlier studies suggested that the insulin gene promoter
is uniquely unmethylated in insulin-expressing pancreatic β-cells,
providing a classic example of this paradigm. Here we show that
islet cells expressing insulin, glucagon, or somatostatin share a lack
of methylation at the promoters of the insulin and glucagon genes.
This is achieved by rapid demethylation of the insulin and glucagon
gene promoters during differentiation of Neurogenin3+ embryonic
endocrine progenitors, regardless of the specific endocrine cell-type
chosen. Similar methylation dynamics were observed in transgenic
mice containing a human insulin promoter fragment, pointing to
the responsible cis element. Whole-methylome comparison of hu-
man α- and β-cells revealed generality of the findings: genes active
in one cell type and silent in the other tend to share demethylated
promoters, while methylation differences between α- and β-cells
are concentrated in enhancers. These findings suggest an epigenetic
basis for the observed plastic identity of islet cell types, and have
implications for β-cell reprogramming in diabetes and diagnosis of
β-cell death using methylation patterns of circulating DNA.
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DNA methylation at CpG sites in gene promoters is a fun-damental epigenetic mark, ensuring cell-type–specific gene-
expression patterns. Following genome-wide demethylation
before implantation of the embryo and global de novo methyl-
ation postimplantation, specific gene promoters are demethy-
lated in cells that will express these genes (1). The stable
inheritance of methylation patterns throughout life is tightly
linked to the stability of cell identity, and poses a barrier to cell-
type conversions (1). This arrangement has important ramifica-
tions for the field of regenerative medicine, as it implies that
forced conversion of cells to a desired new identity must involve
the reprogramming of their methylation patterns.
The methylation pattern of pancreatic β-cells provides a classic
example of the relationship between promoter methylation and
cell identity. β-Cells residing in the islets of Langerhans are the
only source of insulin in the body, and their deficiency is a
hallmark of diabetes. An early study by Gilbert and colleagues
(2) has shown that the promoters of the two rat insulin genes are
unmethylated in insulin-expressing cell lines, and are methylated
in multiple nonexpressing tissues. More recently, methylated
reporter constructs were used to demonstrate that promoter
methylation can prevent insulin expression in β-cell lines (3).
Thus, it is assumed that lack of methylation at the insulin gene
promoter is a unique feature of β-cell identity, similar to the
situation in other cell types expressing unique genes. In the
context of cell therapy for diabetes, the reprogramming of dif-
ferent cell types to transplantable β-cells will likely require
demethylation of the insulin gene promoter; alternatively, cell
types in which the insulin promoter is unmethylated from the
start (none known so far) might be attractive permissive candi-
dates for reprogramming efforts.
Here we investigate the dynamics of promoter methylation in islet
cell genes, using FACS-purified cells from mice and humans. Sur-
prisingly, we find that the promoters of most α- and β-cell–specific
genes are not hypomethylated only in the expressing cell type.
Rather, these gene promoters undergo demethylation in both α- and
β-cells, reflecting cell lineage and a potential for activation, but not
actual expression. Finally, using global methylome analysis, we find
that differential methylation in α- and β-cells is concentrated mostly
in enhancer regions involved in the regulation of cell-type–specific
gene expression. These findings may explain recent reports on
spontaneous conversion of β-cells in diabetes to other islet cell types
(but not to other lineages) (4), and on reprogramming of α- and
δ-cells (but not other endoderm-derived cells) to β-cells (5, 6).
Results
Methylation of Insulin and Glucagon Gene Promoters. To study
methylation patterns in a pure population of primary islet cells, we
sorted cells from dissociated mouse and human islets following
intracellular immunostaining for specific hormones (Fig. S1). We
extracted genomic DNA from sorted cells and examined the
methylation status of CpG sites at the promoters of hormone genes
by bisulfite sequencing (7) and by pyrosequencing (8). As expected,
the ins2 gene promoter was unmethylated in mouse β-cells as well
as in the mouse β-cell line Min6, and was almost fully methylated in
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DNA from mouse exocrine pancreas and tail fibroblasts (Fig. 1 A
and B). A similar pattern was observed in human cells: the insulin
gene promoter was unmethylated in β-cells, and was heavily
methylated in DNA from pancreatic ducts, pancreatic exocrine
tissue, and leukocytes (Fig. 1 C–E). Surprisingly, the insulin gene
promoter was unmethylated in sorted glucagon+ and somatostatin+
cells from human islets (Fig. 1 C–E). Mouse α-cells and the mouse
α-cell line αTC2 showed a low level of methylation at the insulin
promoter, consistent with the results in human α-cells (Fig. 1 A and
B). Thus, the insulin gene promoter is unexpectedly unmethylated
in both α- and β-cells of mice and humans.
To examine whether the similarity in methylation among dif-
ferent islet cell types extends beyond the insulin promoter, we
determined the status of methylation at the glucagon gene pro-
moter. Consistent with observations at the insulin promoter, the
glucagon promoter was unmethylated not only in the mouse
α-cell line, but also in primary mouse α- and β-cells, while
showing complete methylation in the murine exocrine pancreas
and in tail fibroblasts (Fig. 2 A and B). Human cells showed a
similar pattern: the glucagon gene promoter was unmethylated
in α-cells, as well as in β- and δ-cells; the exocrine pancreas and
leukocytes were heavily methylated (Fig. 2 C and D).
Interestingly, CpG sites downstream to the transcription start
sites of the glucagon and insulin gene promoters showed a
methylation pattern that did reflect expression: β-cells lacked
methylation at these sites in the insulin promoter, while insulin−
islet cells were methylated (Fig. 1). Similarly α-cells lacked
methylation at the sites downstream to the transcription start site
of glucagon promoter, while glucagon− islet cells were fully
methylated (Fig. 2 A, C, and D). Thus, pancreatic islet cells share
lack of methylation upstream to the transcription start site of in-
sulin and glucagon gene promoters, regardless of actual expres-
sion. However, the methylation of CpG sites downstream to the
transcription start site of glucagon and insulin genes does corre-
late with expression. These patterns contrast with the complete
methylation of hormone gene promoters in nonislet tissues.
Dynamics of Methylation During Development. If hormone gene
promoters are unmethylated in all islet cell types and not only in
cells that express a particular hormone, it is likely that the underlying
mechanism operates at the level of the pancreatic endocrine lineage,
which is established during late embryogenesis. To understand the
dynamics of methylation at hormone gene promoters during de-
velopment, we analyzed DNA methylation in multiple develop-
mental stages. As shown in Fig. 3 and Fig. S3, the insulin and
glucagon promoters were heavily methylated in murine embryonic
stem cells (ES cells), in endoderm derived from ES cells, and in
Pdx1+ progenitor cells isolated from the pancreas of embryonic day
12.5 (E12.5) mice. Neurogenin3+ (NeuroG3+, NGN3+) endocrine
progenitor cells in E16.5 embryos were also fully methylated at the
insulin and glucagon promoters. Strikingly, the immediate progeny
of Neurog3+ cells, namely insulin+ and glucagon+ cells at E16.5 and
in newborn mice (NB, postnatal day 1), showed a complete lack of
methylation at the insulin and glucagon gene promoters upstream to
the transcription start site (Fig. 3 A–C). Thus, hormone gene pro-
moters undergo rapid demethylation as progenitor cells shut off
Neurog3 expression and turn on hormone gene expression, re-
gardless of the specific hormone selected for expression. Endocrine
differentiation of Neurog3+ cells occurs with minimal cell division
(9, 10), suggesting an active demethylation mechanism. In support of
a rapid process of demethylation, immunostaining showed a di-
chotomy between Neurog3+ cells and hormone-expressing cells in
the embryonic pancreas, with no evidence of intermediate cell types
coexpressing Neurog3 and hormones (Fig. 3D).
Interestingly, methylation patterns in the upstream regions of
hormone gene promoters became more correlated to expression
with age (Fig. 3C). β-Cells maintained a very low level of
methylation at the insulin promoter (∼5% of CpG sites meth-
ylated), but the glucagon promoter in β-cells gradually gained
methylation (from 5% at E16.5 to ∼20% of the sites in adult
β-cells). Similarly, adult α-cells had low methylation at the glu-
cagon promoter (5% of site methylated), but their insulin pro-
moter became more methylated with age (from 5% at E16.5 to
∼25% in adult α-cells). Nonetheless, methylation of nonex-
pressed hormone gene promoters remained always low com-




Fig. 1. DNA methylation at the insulin gene promoter. (A) Bisulfite se-
quencing of the mouse ins2 gene promoter, containing eight CpGs from
positions −411 to +344 relative to the transcription start site (arrow). αTC2,
mouse α-cell line; α-cells, sorted glucagon+ cells from adult mice; MIN6,
mouse β-cell line; β-cells, sorted insulin+ cells from adult mice; pancreas,
largely exocrine pancreas; tail, fibroblasts from a mouse tail biopsy. Each
horizontal line represents a single DNA molecule. Empty circles, unmethy-
lated CpGs; filled circles, methylated CpGs. (B) DNA methylation status of
individual CpG sites in the mouse ins2 gene promoter, quantified using
pyrosequencing on DNA extracted from the indicated sources. Bars repre-
sent average and SE of three independent experiments. Mouse α-cells dif-
fered significantly (P < 0.005) from total pancreas in their methylation level
at the −411, −179, −168, and +314 sites, but not in the +341 and +344 sites.
(C) Bisulfite sequencing of the human insulin gene promoter, containing 13
CpG dinucleotides from positions −234 to +404 relative to the transcription
start site (arrow). α-, β-, and δ-cells are glucagon+, insulin+, and
somatostatin+ cells from human islets, sorted after intracellular staining for
hormones. Leuko, leukocytes. (D) DNA methylation status of individual CpG
sites in the human insulin promoter using pyrosequencing. Bars represent
the average and SE from three independent experiments. Human α-cells
differed significantly (P < 0.005) from total human pancreas in their meth-
ylation level at the −234, −206 and −19 sites, but not in the +127 and
+139 sites. (E) DNA methylation status of individual CpG sites in the human
insulin promoter using illumina 450k methylation array. Values represent
the average methylation level per site from two to three arrays.
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In summary, hormone gene promoters are promptly deme-
thylated in progeny of Neurog3+ endocrine progenitor cells, via a
mechanism that is likely active, and does not depend on ex-
pression from the particular promoter (model in Fig. 3E). With
time, the upstream promoter region of unexpressed hormones
accumulate low levels of methylation. In contrast, methylation
downstream of transcription start sites does reflect expression.
Human Insulin Promoter Demethylation in Transgenic Mice. To de-
fine the cis elements responsible for the pan-islet demethylation of
hormone gene promoters, we generated transgenic mice in which
a short fragment of the human insulin gene promoter (−366 to
+42) drives EGFP expression (Fig. 4A). As expected, EGFP was
expressed specifically in β-cells of transgenic mice (Fig. 4B).
Strikingly, sorting experiments revealed that the human promoter
fragment was unmethylated in both β- and α-cells, despite un-
detectable expression in the latter cells. The transgene was com-
pletely methylated in nonendocrine cells found in islets and in tail
tissue (Fig. 4C). These results are consistent with our observations
that the endogenous mouse and human insulin promoters are
unmethylated in both α- and β-cells. Importantly, they point to a
short sequence at the insulin gene promoter (11), as the respon-
sible cis regulatory element mediating lineage-specific, expression-
independent demethylation. Despite the unmethylated state of
the transgene in α-cells, no EGFP was observed in this cell type,
suggesting that cell-type–specific transcription factors are likely
responsible for the differential expression (12).
Global Comparison of DNA Methylation Profiles in Human α- and
β-Cells. To assess the relationship between DNA methylation
and gene expression in α- and β-cells on a global level, we per-
formed a whole methylome analysis of isolated pancreatic cell
types. We used immunostaining and FACS to isolate β-cells (n =
3 donors), α-cells (n = 2 donors), duct cells (n = 1), acinar cells
(n = 1), and leukocytes (n = 2), and extracted genomic DNA. We
then obtained the methylomes of these samples using the Illu-
mina Infinium HumanMethylation450 BeadChip array, which
reports on the methylation levels of over 450,000 CpG sites in
the genome. Hierarchical clustering analysis showed that α-cells
and β-cells cluster together (Fig. 5A), implying that they have
similar global DNA methylation profiles. However, the β-cell
samples and the α-cell samples can be separated into two in-
dependent clusters, indicating differences in the DNA methyl-
ation between the two cell types. As two of the β-cell samples
(β1 and β2) came from the same donors as the two α-cell sam-




Fig. 3. Methylation dynamics of insulin and glucagon gene promoters
during mouse development. (A) DNA methylation status of CpG sites in the
mouse insulin gene promoter determined by bisulfite sequencing. ES cells,
undifferentiated mouse ES cells; endoderm, mouse ES cells directed to dif-
ferentiate to endoderm as previously described (33); other samples describe
embryonic date of material and marker according to which cells were sorted
(Materials and Methods). Shades of circles represent methylation level
(0% methylated white, 100% methylated black). (B) DNA methylation of
the mouse glucagon gene promoter, using the same samples as in A.
(C) Quantification of DNA methylation in CpG sites upstream to the transcrip-
tion start site of the insulin and glucagon promoters during mouse devel-
opment. (D) Staining for insulin (green), glucagon (red), NeuroG3 (white),
and DNA in (DAPI, blue) in E16.5 mouse pancreas. (Magnification: 40×.) There
is no overlap between NeuroG3 and hormone expression, indicating a rapid
switch from progenitor cells to hormone-producing cells. (E) Model for
lineage-specific methylation dynamics of hormone gene promoters. The im-
mediate progeny of Neurog3+ endocrine progenitor cells undergo active
demethylation at the promoters of hormone genes. Demethylation of hor-
mone gene promoters is not associated with expression, but with a potential
for expression in the particular tissue. Filled and empty lollipops represent
methylated and unmethylated promoters, respectively.
A B
C D
Fig. 2. DNA methylation at the glucagon gene promoter. (A) Bisulfite se-
quencing of nine CpG dinucleotides in the mouse glucagon promoter, from
positions −320 to +109. (B) Methylation status of individual CpG sites in the
mouse glucagon promoter, quantified using pyrosequencing. Bars represent
the average and SE from three independent experiments. Mouse β-cells
differed significantly (P < 0.005) from total pancreas in their methylation
level at all sites examined. (C) Bisulfite sequencing of CpG sites in the human
glucagon promoter, from positions −356 to +271. (D) Methylation status of
individual CpG sites in the human glucagon promoter, quantified using
pyrosequencing. Bars represent the average and SE from three independent
experiments. Human β-cells differed significantly (P < 0.005) from total
pancreas in their methylation level at the −27 and −76 sites.











contributes more to the global methylation profiles than genetic
identity.
We initially examined the methylation status of CpG sites in the
promoter regions of 1,447 genes (10,877 CpGs) that are expressed in
β-cells and silent in α-cells (13) (Fig. 5B). Most of these promoters
were not differentially methylated between β-cells and the exocrine
pancreas. Fig. 5B shows the 40 gene promoters (73 CpGs) that were
methylated in exocrine pancreas and hypomethylated in β-cells. Of
these, the majority (31 gene promoters containing 61 CpGs) were
also hypomethylated in α-cells, while only nine promoters (con-
taining 12 CpGs) were methylated in α-cells (that is, were uniquely
hypomethylated in β-cells). In other words, genes expressed only in
β-cells that are differentially methylated in β-cells and the exocrine
pancreas are usually unmethylated in α-cells, similarly to the insulin
gene promoter. Fig. S2 shows validation of the methylation status of
the β-cell–specific gene SLC2A2 (Glut2), one of the few genes
whose promoter methylation does reflect its expression in β-cells
(and liver) and not in α-cells or the exocrine pancreas.
We carried out a similar analysis of the promoter regions of
1,184 genes (8,608 CpGs) expressed in α-cells but not in β-cells (Fig.
5C). Of the 37 gene promoters that were unmethylated in α-cells
and methylated in the exocrine pancreas, 31 promoters (containing
51 CpGs) were hypomethylated in both β-cells and α-cells, while
only 6 gene promoters (containing 10 CpGs) were uniquely hypo-
methylated in α-cells. Thus, most promoter regions of cell-type–
specific genes are unmethyalted in α- and β-cells regardless of their
expression profile, similarly to our findings with the insulin and
glucagon gene promoters.
We then performed a global methylation analysis to identify
the sites that are hypomethylated in α-cells, β-cells, or in both cell
types relative to the exocrine pancreas, regardless of association
with genes and expression patterns (Fig. 6A). Among over
450,000 sites analyzed from all autosomal chromosomes, we found
745 sites uniquely hypomethylated in β-cells, 353 sites uniquely
hypomethylated in α-cells, and 3,753 sites commonly hypomethy-
lated in both cell types. Thus, similar to the situation in promoters
of cell-type–specific genes, islet-specific hypomethylation is more
common than islet cell-type–specific hypomethylation.
We investigated the nature of the genomic regions that contain
differentially methylated CpG sites in α- and β-cells. The majority
of differentially methylated regions (DMRs, 75%) were located in
gene bodies or in intergenic regions, while only 50% of the sites
analyzed in the array are located in gene bodies or intergenic
regions (Fig. 6B and Dataset S1). Since in mammals enhancers are
distributed in both gene bodies and intergenic regions (14), we
propose that the DMRs of α- and β-cells are located in distal
regulatory regions rather than in promoter regions.
Since active enhancers are specifically labeled with histone
H3K4me1 and H3K27Ac, while poised enhancers are labeled with
H3K4me1 (14), we compared methylation patterns to the published
distribution of these chromatin marks in human pancreatic islets
(15). The α- and β-DMRs were highly enriched in histone
H3K4me1 and H3K27Ac (P < 3.00e-08 and 8.89e-30, respectively)
(Dataset S1), supporting the idea that an important part of islet
cell-type identity is based on differential methylation in enhancer
elements rather than in promoters (Fig. 6B and Dataset S1).
To further examine the correlation between methylation and en-
hancer activity in β-cells, we analyzed DNAmethylation andH3K27ac
levels at enhancer regions, which are marked with H3K4me1. We
found that DNA methylation in β-cells and H3K27ac in pancreatic
islets are negatively correlated (P < 2.2e-16) (Fig. 6 C and D and Fig.
S4), suggesting that hypomethylation of enhancer regions is related to
their activity.
Furthermore, we found that differential methylation of en-
hancers is associated with differential gene expression in α- and




Fig. 4. DNA methylation in transgenic mice carrying a human insulin pro-
moter fragment. (A) Schematic of the transgene. Arrow represents tran-
scription start site of the human insulin gene. (B) Immunofluorescence
analysis of insulin, glucagon, and GFP expression in pancreatic sections from
transgenic mice. (Magnification: 40×.) GFP is expressed exclusively in β-cells.
(C) Methylation status of the human insulin promoter in transgenic mice.
Dissociated islet cells were sorted using intracellular hormone immunos-
taining into α-cells, β-cells, and hormone-negative cells. In addition, tail
fibroblasts were used. Similar results were obtained from a second, in-
dependent founder transgenic line. A
B C
Fig. 5. Global analysis of DNA methylation in promoters of cell-type–specific
genes. (A) Dendrogram showing hierarchical clustering (Ward’s method) of
α-cells, β-cells, pancreatic duct and acinar cells, and leukocytes. The y axis shows
Euclidian distance between samples. (B) Methylation heatmap of promoters
expressed in β-cells and silent in α-cells. Shown are only the promoters that are
hypomethylated in α- or β-cells compared with whole pancreas. Methylation of
these sites is also shown for blood, liver, muscle, fat, and spleen. INS refers to
one CpG site (different from the cluster of sites in the promoter discussed
earlier). (C) Heatmap of CpG sites hypomethylated in α-cells, β-cells, or in both
cell types compared with whole pancreas, in the promoters of genes expressed
in α-cells and silent in β-cells. Methylation of these sites is also shown for blood,
liver, muscle, fat, and spleen. GCG refers to one CpG site (different from the
cluster of sites in the promoter discussed earlier).
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whose nearest gene is expressed specifically in β-cells, and found
that many CpGs are in these regions are uniquely hypomethylated
in β-cells (P < 2.2e-26) (Fig. 6E).
We also found differentially methylated enhancers near genes
that are expressed specifically in β-cells and show promoter
hypomethylation in both α- and β-cells relative to the exocrine
pancreas (Fig. 6F). This indicates that cell-type–specific gene
expression relies on differentially methylated enhancers rather
than on differential methylation in promoters.
Discussion
We show here that α- and β-cells in the islets of Langerhans
share a similar DNA methylation pattern in gene promoters,
which extends beyond the genes that these cells commonly ex-
press. Genes uniquely expressed in just one of these cell types—
insulin and glucagon being prime examples—tend to have their
promoters hypomethylated in both cell types, while methylated
in other tissues. Thus, promoter hypomethylation in α- and
β-cells is associated with the islet lineage, not with actual gene
expression as classically described (1). We note that lineage-
specific, expression-independent methylation patterns have been
described in other organ systems; for example, certain promoters
are unmethylated in both T and B cells, despite being expressed in
only one of these sublineages (16).
The differences between α- and β-cell methylation are found
more in enhancers, consistent with evidence from other organ
systems. Indeed, analysis of tissue-specific DMRs showed that
they are predominantly regulatory elements located intergeni-
cally, that their DNA methylation state is variable among dif-
ferent cell types (17), and that they are enriched for the histone
modifications H3K4me1 and H3K27ac (18).
Furthermore, the observation that differential methylation of
enhancers is associated with differential expression of pancreatic
α- and β-cells supports the idea that an important part of islet
cell-type identity is based on differential methylation in enhancer
elements, rather than in promoters.
The molecular mechanisms responsible for lineage-specific
promoter demethylation remain to be defined, but certain im-
portant properties are already clear. First, since NeuroG3+ cells
are only minimally dividing (19) and since newly formed
hormone-expressing cells already lack methylation (Fig. 3),
demethylation in this case is likely an active and rapid process.
Second, the possible recruitment of demethylase activity to
hormone gene promoters is unlikely to rely on cell-type–specific
transcription factors, since the same promoters undergo
demethylation in both α- and β-cells. We therefore predict that
demethylation in the pancreas is mediated by sequence-specific
factors which are direct targets of NeuroG3, and are present at
least transiently in all progeny of endocrine progenitors, for
example Nkx2.2 or NeuroD1. Our identification of a 400-bp
fragment of the human insulin promoter that is sufficient to
drive demethylation in both β-cells and α-cells will aid in the
search for the responsible factors.
What is the physiological significance of hormone gene pro-
moter demethylation? Lack of methylation at the insulin gene
promoter is important for insulin expression in β-cells (3).
However, β-cells will normally never express glucagon nor will
α-cells express insulin. It appears therefore that promoter
demethylation of islet genes is part of the generic specification
program of the islet lineage. While the status of promoter
methylation does not dictate gene expression, we propose that it
does define a potential for gene expression. Such a situation may
explain in part recent evidence on the plasticity of islet cell-type
A
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Fig. 6. Characterization of CpG sites differentially methylated in human α-
and β-cells. (A) Heatmap of CpG sites hypomethylated in α-cells, β-cells, or in
both cell types compared with whole pancreas. (B) Genome-wide distribu-
tion of CpG sites that are differentially methylated in α- and β-cells compared
with the exocrine pancreas. (Upper) Association of differentially methylated
sites with distal and proximal promoters, gene bodies, and intergenic re-
gions. (Lower) Association of differentially methylated sites with enhancer
regions in α- and β-cells, as defined by the presence of histone H3K4me1,
H3K27Ac, or both marks. Body, gene body; Dist, distal promoter; Inter,
intergenic region; Prox, proximal promoter. (C) Negative correlation of DNA
methylation and enhancer activity. DNA methylation of β-cells and H3K27ac
levels of islets were analyzed at enhancer regions (regions marked with
H3K4me1 in islets). Locally smoothed means (red) and SDs (blue) of DNA
methylation and H3K27ac at enhancer regions are plotted. DNA methylation
and H3K27ac are negatively correlated (R = −0.2300397, P < 2.2e-16).
(D) Levels of H3K27ac (reads per kilobase and million mapped reads) plotted in
10-bp blocks 3,000-bp downstream and upstream of H3K4me1 peaks either
methylated (met, 4,527 peaks, >80% DNA methylation) or unmethylated
(unmet, 8,022 peaks, <20% DNA methylation) in β-cells. Regions surround-
ing unmethylated peaks appear to be highly marked with H3K27ac. (E) A
volcano plot showing differential methylation of α and β-cells at enhancers
whose nearest gene is expressed specifically in β-cells. The 396 sites related to
192 different genes are hypomethylated specifically in β-cells [false-discovery
rate (FDR) < 0. 05]. In contrast, only 46 sites are specifically hypomethylated
in α-cells (P < 2.2e-26, binomial test). (F) Methylation of enhancers near genes
with hypomethylated promoters in both α- and β-cells is associated with dif-
ferential expression. A volcano plot showing differential methylation in α- and
β-cells at enhancers whose nearest gene is expressed specifically in β-cells and
is hypomethylated in both α- and β-cells. Among 29 candidate genes, 10 have
enhancers with CpGs hypomethylated in β-cells (23 different CpG sites),
while only 3 genes have enhancers with CpGs hypomethylated in α-cells
(6 CpG sites) (P = 0.001887, binomial test).











identity. β-Cell reprogramming to alternative islet cell fates was
suggested to account for β-cell failure in type 2 diabetes (4, 20–
22). In the opposite direction, α- and δ-cells spontaneously re-
program to β-cells after near-total ablation of β-cells in mice (5,
6). Importantly, and unexplained so far, plasticity in both sce-
narios is confined to islet cells (23). We thus propose that hard-
wired promoter methylation status plays a part in restricting
plasticity to the islet lineage.
Moreover, the common status of promoter methylation in islet
cells may have implications for attempts to reprogram other cell
types to β-cells, which have proven challenging so far. Our results
suggest that extraislet cells, such as hepatocytes, neurons, and exo-
crine pancreatic cells have a higher barrier for reprogramming into
β-cells, as demethylation of the insulin and other gene promoters
will be required, on top of supplying the transacting transcriptional
machinery of β-cells. We propose that non–β-cells in islets, such as
α- and δ-cells, represent a preferred starting material for reprog-
ramming toward β-cells, given their a priori lack of methylation at
the insulin promoter. This view is consistent with the finding that the
overall chromatin make-up and transcriptome of β-cells and α-cells
are highly similar (15). How enhancer methylation status, which
shows more cell-type specificity, interphases with cell reprogram-
ming is an interesting topic that requires further investigation.
The findings also have implications for the emerging field of
β-cell death diagnosis based on detection of methylation patterns
in circulating DNA (24–28). The cytosines in the insulin gene
that were previously used to identify β-cell–derived DNA circu-
lating in plasma are indeed β-cell–specific (methylated in all
other tissues examined, including α-cells; positions +304 to
+404). However, when searching for additional methylation sites
that can serve as markers of β- or α-cell death, the similarity and
differences in the methylomes of β-cells and other islet cells must
be taken into account.
In conclusion, promoters of islet cell genes, including those
encoding hormones, are rapidly demethylated during the dif-
ferentiation of Neurog3+ endocrine progenitor cells. Demethy-
lation is independent of future gene expression, and marks the
differentiated islet cell lineage. Methylation differences between
islet cell types are concentrated in enhancer elements. Lineage-
specific epigenetic patterns may indicate the potential capacity of
cells for reprogramming toward β-cells and other desired fates.
Materials and Methods
Cadaveric human islets, cell lines, and mouse tissues were processed for DNA
extraction and bisulfite treatment, as detailed in SI Materials and Methods.
Methylation was assessed using sequencing of bacterial clones, pyrose-
quencing or Illumina 450k arrays. For the 450k arrays, we processed raw data
using RnBeads (29), substracted background using the noob method from
the methylumi package (30), and normalized using BMIQ (31). Hierarchical
clustering was performed using Ward’s minimum variance method with
Euclidian distances. Differential methylation was performed using the
RnBeads package. Chip-seq data for H3K4me1 and H3K27ac in pancreatic
islets was downloaded fromArray Express (https://www.ebi.ac.uk/arrayexpress/),
accession no. E-MTAB-1919. Peaks were called using SICER (32).
Animal experiments were approved by the Institutional Animal Care and
Use Committee of the Hebrew University. The Hebrew University is an As-
sociation for Assessment and Accreditation of Laboratory Animal Care
International-accredited institute.
ACKNOWLEDGMENTS. We thank S. Efrat for the gift of αTC and Min6 cells.
This work was funded by grants from the NIH β-Cell Biology Consortium
(“MAPLE”, VUMC38149), the Human Islet Research Network, European Union
FP7 Program (Grant 241883), the European Research Council (BetaToBeta,
STG260685), the Juvenile Diabetes Research Foundation, the Britain–Israel Re-
search and Academic Exchange, the Helmsley Trust, Dutch friends of Hebrew
University, the DON Foundation, and the Israel Science Foundation (41.11).
1. Cedar H, Bergman Y (2012) Programming of DNA methylation patterns. Annu Rev
Biochem 81:97–117.
2. Cate RL, Chick W, Gilbert W (1983) Comparison of the methylation patterns of the
two rat insulin genes. J Biol Chem 258:6645–6652.
3. Kuroda A, et al. (2009) Insulin gene expression is regulated by DNA methylation. PLoS
One 4:e6953.
4. Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic β cell dedifferentiation as
a mechanism of diabetic β cell failure. Cell 150:1223–1234.
5. Thorel F, et al. (2010) Conversion of adult pancreatic alpha-cells to beta-cells after
extreme beta-cell loss. Nature 464:1149–1154.
6. Chera S, et al. (2014) Diabetes recovery by age-dependent conversion of pancreatic
δ-cells into insulin producers. Nature 514:503–507.
7. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methyl-
ated cytosines. Nucleic Acids Res 22:2990–2997.
8. Ronaghi M, Uhlen M, Nyren P (1998) A sequencing method based on real-time py-
rophosphate. Science 281:363–365.
9. Gradwohl G, Dierich A, LeMeur M, Guillemot F (2000) neurogenin3 is required for the
development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci
USA 97:1607–1611.
10. Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic lineage:
NGN3+ cells are islet progenitors and are distinct from duct progenitors.
Development 129:2447–2457.
11. Hay CW, Docherty K (2006) Comparative analysis of insulin gene promoters: Impli-
cations for diabetes research. Diabetes 55:3201–3213.
12. Aramata S, Han SI, Yasuda K, Kataoka K (2005) Synergistic activation of the insulin
gene promoter by the beta-cell enriched transcription factors MafA, Beta2, and Pdx1.
Biochim Biophys Acta 1730:41–46.
13. Dorrell C, et al. (2011) Transcriptomes of the major human pancreatic cell types.
Diabetologia 54:2832–2844.
14. Heintzman ND, et al. (2007) Distinct and predictive chromatin signatures of tran-
scriptional promoters and enhancers in the human genome. Nat Genet 39:311–318.
15. Bramswig NC, et al. (2013) Epigenomic plasticity enables human pancreatic α to β cell
reprogramming. J Clin Invest 123:1275–1284.
16. Bock C, et al. (2012) DNA methylation dynamics during in vivo differentiation of
blood and skin stem cells. Mol Cell 47:633–647.
17. Liu H, et al. (2016) Systematic identification and annotation of human methylation
marks based on bisulfite sequencing methylomes reveals distinct roles of cell type-
specific hypomethylation in the regulation of cell identity genes. Nucleic Acids Res 44:
75–94.
18. Hon GC, et al. (2013) Epigenetic memory at embryonic enhancers identified in DNA
methylation maps from adult mouse tissues. Nat Genet 45:1198–1206.
19. Miyatsuka T, Kosaka Y, Kim H, German MS (2011) Neurogenin3 inhibits proliferation
in endocrine progenitors by inducing Cdkn1a. Proc Natl Acad Sci USA 108:185–190.
20. Cinti F, et al. (2016) Evidence of β-cell dedifferentiation in human type 2 diabetes.
J Clin Endocrinol Metab 101:1044–1054.
21. Wang Z, York NW, Nichols CG, Remedi MS (2014) Pancreatic β cell dedifferentiation in
diabetes and redifferentiation following insulin therapy. Cell Metab 19:872–882.
22. Dor Y, Glaser B (2013) β-Cell dedifferentiation and type 2 diabetes. N Engl J Med 368:
572–573.
23. Ziv O, Glaser B, Dor Y (2013) The plastic pancreas. Dev Cell 26:3–7.
24. Herold KC, et al.; Type 1 Diabetes TrialNet Study Group (2015) β Cell death and
dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest
125:1163–1173.
25. Akirav EM, et al. (2011) Detection of β cell death in diabetes using differentially
methylated circulating DNA. Proc Natl Acad Sci USA 108:19018–19023.
26. Lehmann-Werman R, et al. (2016) Identification of tissue-specific cell death using
methylation patterns of circulating DNA. Proc Natl Acad Sci USA 113:E1826–E1834.
27. Fisher MM, et al. (2015) Elevations in circulating methylated and unmethylated pre-
proinsulin DNA in new-onset type 1 diabetes. Diabetes 64:3867–3872.
28. Husseiny MI, Kaye A, Zebadua E, Kandeel F, Ferreri K (2014) Tissue-specific methyl-
ation of human insulin gene and PCR assay for monitoring beta cell death. PLoS One
9:e94591.
29. Assenov Y, et al. (2014) Comprehensive analysis of DNA methylation data with
RnBeads. Nat Methods 11:1138–1140.
30. Davis S, Du P, Bilke S, Triche T, Bootwalla M (2016) methylumi: Handle Illumina
Methylation Data. R package Version 2.20.0. Available at https://rdrr.io/bioc/methylumi.
Accessed November 19, 2017.
31. Teschendorff AE, et al. (2013) A beta-mixture quantile normalization method for
correcting probe design bias in Illumina Infinium 450 k DNA methylation data.
Bioinformatics 29:189–196.
32. Xu S, Grullon S, Ge K, Peng W (2014) Spatial clustering for identification of ChIP-
enriched regions (SICER) to map regions of histone methylation patterns in embryonic
stem cells. Methods Mol Biol 1150:97–111.
33. Borowiak M, et al. (2009) Small molecules efficiently direct endodermal differentia-
tion of mouse and human embryonic stem cells. Cell Stem Cell 4:348–358.
34. Powers AC, et al. (1990) Proglucagon processing similar to normal islets in pancreatic
alpha-like cell line derived from transgenic mouse tumor. Diabetes 39:406–414.
35. Reimann F, et al. (2008) Glucose sensing in L cells: A primary cell study. Cell Metab 8:
532–539.
36. Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2:
2265–2275.
37. Smyth GK, Michaud J, Scott HS (2005) Use of within-array replicate spots for assessing
differential expression in microarray experiments. Bioinformatics 21:2067–2075.
13530 | www.pnas.org/cgi/doi/10.1073/pnas.1713736114 Neiman et al.
